📰 Nasdaq Rxrx News
Nasdaq Rxrx News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Rxrx. Real-time updates on events, politics, business and more.
May 4, 2024
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares […]
April 21, 2024
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the sale, the director now directly owns 7,229,861 shares in the […]
March 11, 2024
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 6.1% during trading on Monday following insider selling activity. The stock traded as low as $10.50 and last traded at $10.51. Approximately 3,359,534 shares changed hands during trading, a decline of 54% from the average daily volume of 7,262,308 shares. The stock had previously […]
March 11, 2024
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) dropped 6.1% during trading on Monday after an insider sold shares in the company. The company traded as low as $10.50 and last traded at $10.51. Approximately 3,359,534 shares traded hands during trading, a decline of 54% from the average daily volume of 7,262,308 shares. […]
February 29, 2024
Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its target price upped by Needham & Company LLC from $15.00 to $17.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently issued reports on RXRX. TD Cowen initiated coverage on Recursion Pharmaceuticals […]
February 27, 2024
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second...
February 24, 2024
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) COO Tina Marriott sold 8,000 shares of the firm’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $14.89, for a total value of $119,120.00. Following the completion of the sale, the chief operating officer now owns 639,982 shares […]
February 16, 2024
Baillie Gifford & Co. lowered its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,551,409 shares of the company’s stock after selling 546,221 shares during the quarter. Baillie Gifford & […]
February 16, 2024
Baillie Gifford & Co. lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 2.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 24,551,409 shares of the company’s stock after selling 546,221 shares during the period. Baillie Gifford & Co. owned approximately 11.39% […]
February 1, 2024
Wealthspire Advisors LLC bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,327 shares of the company’s stock, valued at approximately $87,000. Other institutional investors and hedge funds have […]